Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: A meta-analysis of randomised controlled trials

The Lancet

Volumn 387, Issue 10018, 2016, Pages 537-544

  Cassese, Salvatore ^a   Byrne, Robert A ^a   Ndrepepa, Gjin ^a   Kufner, Sebastian ^a   Wiebe, Jens ^a   Repp, Janika ^a   Schunkert, Heribert ^a,b   Fusaro, Massimiliano ^a   Kimura, Takeshi ^c   Kastrati, Adnan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRULOG; INOTROPIC AGENT; THIENOPYRIDINE DERIVATIVE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BIORESORBABLE SCAFFOLD; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DEVICE COMPARISON; DEVICE SAFETY; EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD; EVEROLIMUS ELUTING CORONARY STENT; EVEROLIMUS ELUTING METALLIC STENT; FOLLOW UP; HEALTH CARE QUALITY; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; IN DEVICE LATE LUMEN LOSS; ISCHEMIC HEART DISEASE; META ANALYSIS; METAL STENT; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STENOSIS; STENT COMPLICATION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGED; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; DEVICES; DRUG ELUTING STENT; FEMALE; GRAFT OCCLUSION, VASCULAR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROCEDURES; REOPERATION; STATISTICS AND NUMERICAL DATA; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; AGED; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REOPERATION; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84959477205     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00979-4     Document Type: Article

References (23)

1. S Windecker, P Kolh, F Alfonso et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
2. F Otsuka, RA Byrne, K Yahagi et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment Eur Heart J 36 2015 2147 2159
3. J Wiebe, HM Nef, CW Hamm Current status of bioresorbable scaffolds in the treatment of coronary artery disease J Am Coll Cardiol 64 2014 2541 2551
4. J Iqbal, Y Onuma, J Ormiston, A Abizaid, R Waksman, P Serruys Bioresorbable scaffolds: rationale, current status, challenges, and future Eur Heart J 35 2014 765 776
5. D Capodanno, T Gori, H Nef et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry EuroIntervention 10 2015 1144 1153
6. RA Byrne, A Kastrati Bioresorbable drug-eluting stents: an immature technology in need of mature application JACC Cardiovasc Interv 8 2015 198 200
7. PW Serruys, B Chevalier, D Dudek et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
8. M Sabate, S Windecker, A Iniguez et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial Eur Heart J 2015 published online Sept 24. http://dx.doi.org/10.1093/eurheartj/ehv500
9. S Puricel, D Arroyo, N Corpataux et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds J Am Coll Cardiol 65 2015 791 801
10. T Kimura, K Kozuma, K Tanabe et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan Eur Heart J 2015 published online Sept 1. http://dx.doi.org/10.1093/eurheartj/ehv435
11. R Gao, Y Yang, Y Han et al. Randomized comparison of everolimus-eluting Absorb bioresorbable vascular scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: The ABSORB China trial J Am Coll Cardiol 2015 10.1016/j.jacc.2015.09.054 published online Oct 6.
12. S Ellis, D Kereiakes, D Metzger et al. Everolimus-eluting bioresorbable vascular scaffolds in patients with coronary artery disease: The ABSORB III trial N Engl J Med 2015 10.1056/NEJMoa1509038 published online Oct 12.
13. D Moher, A Liberati, J Tetzlaff, DG Altman, P Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 W64.
14. JP Higgins, SG Thompson, JJ Deeks, DG Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
15. P Juni, A Witschi, R Bloch, M Egger The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1999 1054 1060
16. MJ Bradburn, JJ Deeks, JA Berlin, A Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
17. GA Barnard On alleged gains in power from lower p-values Stat Med 8 1989 1469 1477
18. JA Sterne, M Egger, GD Smith Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis BMJ 323 2001 101 105
19. A Booth, M Clarke, D Ghersi, D Moher, M Petticrew, L Stewart An international registry of systematic-review protocols Lancet 377 2011 108 109
20. P Woudstra, MJ Grundeken, RP Kraak et al. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design Am Heart J 167 2014 133 140
21. A Mattesini, GG Secco, G Dall'Ara et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance JACC Cardiovasc Interv 7 2014 741 750
22. PW Serruys, Y Onuma, HM Garcia-Garcia et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months EuroIntervention 9 2014 1271 1284
23. F Otsuka, E Pacheco, LE Perkins et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model Circ Cardiovasc Interv 7 2014 330 342